Back to search results

Beetroot Juice for Angina in Women with Coronary Microvascular Dysfunction

This study is looking at whether inorganic nitrate, given as nitrate-rich beetroot juice, can help women with a type of heart condition called ANOCA (angina with non-obstructive coronary artery disease) and CMD (coronary microvascular dysfunction). These conditions can cause chest pain (angina) and make it hard to exercise. The study wants to see if drinking beetroot juice for 14 days can improve blood flow to the heart, reduce angina and shortness of breath, and improve overall quality of life and physical fitness, compared to a placebo (nitrate-depleted beetroot juice). Participants will drink either the nitrate-rich beetroot juice or the placebo for 14 days, then switch to the other for another 14 days. The main goal is to measure changes in coronary flow reserve, which shows how well blood flows through the heart.

Study design
This is an interventional study with 8 participants. It compares nitrate-rich beetroot juice to a placebo.
What's involved
You would take a study beverage (either nitrate-rich beetroot juice or a placebo) for a total of four weeks.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured from enrollment to day 14.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06948201

Inorganic Nitrate as a Treatment for ANOCA: NO-ANOCA

Not Yet Recruiting
NAAges 18+InterventionalHealth services
University of Virginia
~8 participants
Updated 2025-04-29 on ClinicalTrials.gov
What's tested:70mL Nitrate Rich Beetroot Juice followed by placebo (Nitrate depleted beetroot juice)Placebo (70 mL Nitrate depleted beetroot juice) followed by 70mL Nitrate Rich Beetroot Juice

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in Coronary Flow Reserve
Measured over From enrollment to day 14

Conditions

Coronary Microvascular Dysfunction (CMD)
Angina Patients With Non-obstructive Coronary Artery Disease

Explore related trials

AnginaCoronary microvascular dysfunctionNonocclusive coronary artery atherosclerosis

Where it's being run

1 sites across 1 states
Virginia1

Study leadership

  • Patricia Rodriguez-Lozano, MD · PRINCIPAL_INVESTIGATOR · University of Virginia

Who to contact

Shuo Wang
[email protected]
434-982-1058
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years.
Female sex.
Willing and able to provide written informed consent.
Signs and symptoms of suspected ischemia prompted referral for further evaluation by cardiac catheterization or CCTA within two years of consent.
No evidence of obstructive epicardial CAD (stenosis \>50%) of a major epicardial vessel or an FFR ≤0.80 by invasive catheterization or CCTA. Patients who have not undergone cardiac catheterization of CT angiogram within the last 2 years for chest pain can be scheduled for a screening CT angiogram of the coronary arteries to confirm eligibility.
Impaired coronary flow reserve (cut-off values depending on methodology use between ≤2.0 and ≤2.5 by stress testing PET/CMR or Invasive assessment) or Abnormal index of coronary microcirculatory resistance (e.g., IMR \> 25)
SGLT2i Naïve

Exclusion

History of non-ischemic cardiomyopathy LVEF \<40% or hypertrophic cardiomyopathy.
History of congestive heart failure, severe pulmonary disease, liver disease
History of acute coronary syndrome (ACS) within previous 30 days
Stroke within the last 180 days or intracranial hemorrhage at any time.
Severe valvular disease
Life expectancy \<3 years, due to non-cardiovascular comorbidity.
Pregnancy or women who are breast-feeding
Type 1 diabetes mellitus
Symptomatic hypotension or systolic BP\<95 mmHg on 2 consecutive measurements
Active malignancy requiring treatment at the time of visit
Severe (eGFR \<30 mL/min/1.73 m2 by CKD-EPI), unstable, or rapidly progressing renal disease at the time of randomization
History of recurrent UTI/bladder/kidney infections
Asthma with ongoing wheezing
Known or suspected bronchoconstrictive or bronchospastic lung disease (ARDS, emphysema)
Greater than first degree heart block
Implanted cardiac device
Profound sinus bradycardia (heart rates\<40 beats per minute)
Atrial fibrillation or supraventricular arrhythmias at time of imaging
Known intolerance of nitrates (other than hypotension)
History of reaction to iodinated contrast agents
Any orthopedic, neurological, or other condition that prevents participant from exercising
Individuals currently taking nitroglycerine (or inorganic nitrates), PDE-5 inhibitors (ex: Cialis, Viagra), and xanthine oxidase inhibitors (ex: Allopurinol)
Smokers within the last 5 years
Prisoners
Cognitively impaired individuals
Non-English Speaking

What this trial measures

  • Change in Coronary Flow ReserveFrom enrollment to day 14

    Coronary flow reserve is calculated as the ratio of hyperemic myocardial blood flow to the resting myocardial blood flow using cardiovascular magnetic resonance myocardial perfusion imaging